Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis
Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges lik...
Saved in:
Published in | BMC public health Vol. 24; no. 1; p. 220 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
18.01.2024
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes.
In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves.
Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves.
This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. |
---|---|
AbstractList | Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. Keywords: COVID-19, Vaccination rates, Population-level, United States, Statistical analysis Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. BackgroundPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes.MethodsIn this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves.ResultsOur study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves.ConclusionsThis study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. Methods In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems. Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Results Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally associated with decreased CHR. However, the impact of activity-related engagement levels on COVID-19 health outcomes varied across different waves. Regarding static variables, the social vulnerability index consistently exhibits positive associations with CHR, while Medicaid spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. Conclusions This study concludes that despite the emergence of new variants, vaccines remain highly correlated with reduced COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a critical line of defense for protecting the public and reducing the burden on healthcare systems. |
ArticleNumber | 220 |
Audience | Academic |
Author | Du, Hongru Saiyed, Samee Gardner, Lauren M |
Author_xml | – sequence: 1 givenname: Hongru surname: Du fullname: Du, Hongru email: hdu9@jhu.edu, hdu9@jhu.edu organization: Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA. hdu9@jhu.edu – sequence: 2 givenname: Samee surname: Saiyed fullname: Saiyed, Samee organization: Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA – sequence: 3 givenname: Lauren M surname: Gardner fullname: Gardner, Lauren M organization: Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38238709$$D View this record in MEDLINE/PubMed |
BookMark | eNptUk1v1DAQjVAR_YA_wAFZ4sIlxR9xbHNbbWlZqVIPUK6WY0-6XmXjJXa66o2fjrMpK0DIh7HevPdmRnrnxUkfeiiKtwRfEiLrj5FQKVWJaVUSIRQu9y-KM1IJUtKKy5M__qfFeYwbjImQnL4qTpmkTAqszoqfixiD9Sb50KMG0h6gR4_GWt_P2GASRGR6h5Z331dXJVFoDaZLaxTGZMM2N32P0hrQfe8TOPQ1TYpPyKBd2I3dwaXs4BE6FHPLx-St6bKj6Z6ij6-Ll63pIrx5rhfF_fXnb8sv5e3dzWq5uC0txzKVAnPBW1FZYh0xRAlLmaIZwq6qCAPH60Y03NUNa2njZKuYVLhiBiRvqtayi2I1-7pgNno3-K0ZnnQwXh-AMDxoM-TVOtCAa3DQVqIxtLKCKllzYklruDKcUZa9PsxeuyH8GCEmvfXRQteZHsIYNVVEcM4EF5n6_h_qJoxDvn1iUV5jUmfmkfVg8nzftyENxk6meiEkJSofP429_A8rPwdbb3M2Wp_xvwR0FtghxDhAe7ybYD1FSM8R0jlC-hAhvc-id88bj80W3FHyOzPsF3I9wjU |
CitedBy_id | crossref_primary_10_1016_j_ijid_2024_107163 |
Cites_doi | 10.1016/S1473-3099(22)00320-6 10.1038/s41591-021-01230-y 10.1016/S1473-3099(20)30553-3 10.1056/NEJMc2200133 10.3390/vaccines10050726 10.2139/ssrn.3951778 10.1056/NEJMoa2110345 10.46234/ccdcw2021.255 10.1001/jamanetworkopen.2020.26881 10.1016/j.ebiom.2023.104482 10.1016/S1473-3099(22)00578-3 10.1016/S0140-6736(22)00462-7 10.1016/S0140-6736(21)00947-8 10.1056/NEJMoa2101544 10.1016/j.vaccine.2023.05.056 10.1001/jamanetworkopen.2022.0536 10.1056/NEJMoa2035389 10.1001/jamanetworkopen.2022.28900 10.1016/S0140-6736(23)00461-0 10.1002/jmv.27697 10.1016/S0140-6736(22)01656-7 10.1016/S1473-3099(20)30120-1 10.1056/NEJMoa2203965 10.1016/j.vaccine.2021.05.099 10.3390/ijerph17207560 10.1002/rmv.2146 10.1126/science.abb4218 10.1038/s41586-020-2923-3 10.1371/journal.pone.0253116 10.1371/journal.pmed.1003992 10.1016/j.rceng.2020.08.002 10.1056/NEJMoa2114228 10.1001/jamainternmed.2022.4299 10.1016/S1473-3099(22)00801-5 10.15585/mmwr.mm7034e2 10.1377/hlthaff.2017.1166 |
ContentType | Journal Article |
Copyright | 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7T2 7X7 7XB 88E 8C1 8FE 8FG 8FI 8FJ 8FK ABJCF ABUWG AFKRA AN0 ATCPS AZQEC BENPR BGLVJ BHPHI C1K CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. L6V M0S M1P M7S PATMY PIMPY PQEST PQQKQ PQUKI PRINS PTHSS PYCSY 7X8 DOA |
DOI | 10.1186/s12889-024-17790-w |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Health and Safety Science Abstracts (Full archive) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Public Health Database ProQuest SciTech Collection ProQuest Technology Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Agriculture & Environmental Science Database ProQuest Central Essentials ProQuest Central Technology Collection ProQuest Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Engineering Database Environmental Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student Technology Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest Engineering Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Agricultural & Environmental Science Collection Health & Safety Science Abstracts ProQuest Medical Library (Alumni) Engineering Collection Engineering Database ProQuest Public Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text Coronavirus Research Database ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Environmental Science Collection ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Materials Science & Engineering Collection Environmental Science Database ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 1471-2458 |
EndPage | 220 |
ExternalDocumentID | oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323 A782195753 10_1186_s12889_024_17790_w 38238709 |
Genre | Journal Article |
GeographicLocations | United States United States--US |
GeographicLocations_xml | – name: United States – name: United States--US |
GrantInformation_xml | – fundername: NSF Award grantid: 2229996 – fundername: NSF RAPID Award grantid: 2108526 |
GroupedDBID | --- -A0 0R~ 23N 2WC 2XV 3V. 44B 53G 5VS 6J9 6PF 7X7 7XC 88E 8C1 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAJSJ AAWTL ABDBF ABJCF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACRMQ ADBBV ADINQ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AN0 AOIJS ATCPS BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BNQBC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EMB EMK EMOBN ESTFP ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ITC KQ8 L6V M1P M48 M7S M~E NPM O5R O5S OK1 P2P PATMY PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX CITATION ABMYL ABVAZ AFGXO AFNRJ 7T2 7XB 8FK AZQEC C1K COVID DWQXO GNUQQ K9. PQEST PQUKI PRINS 7X8 |
ID | FETCH-LOGICAL-c508t-70575f74c1cd1a197c239275f0d4413ed56b7b5d6b3f2bd8f9389043ae85b4fc3 |
IEDL.DBID | DOA |
ISSN | 1471-2458 |
IngestDate | Tue Oct 22 15:15:54 EDT 2024 Fri Oct 25 11:08:23 EDT 2024 Thu Oct 10 18:55:46 EDT 2024 Wed Mar 13 18:28:13 EDT 2024 Tue Mar 12 05:00:47 EDT 2024 Thu Sep 12 19:15:07 EDT 2024 Sat Nov 02 12:24:04 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | COVID-19 Statistical analysis Population-level United States Vaccination rates |
Language | English |
License | 2024. The Author(s). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c508t-70575f74c1cd1a197c239275f0d4413ed56b7b5d6b3f2bd8f9389043ae85b4fc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/e06edef47ba24c7298651c1fa59a5323 |
PMID | 38238709 |
PQID | 2925601655 |
PQPubID | 44782 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323 proquest_miscellaneous_2917553757 proquest_journals_2925601655 gale_infotracmisc_A782195753 gale_infotracacademiconefile_A782195753 crossref_primary_10_1186_s12889_024_17790_w pubmed_primary_38238709 |
PublicationCentury | 2000 |
PublicationDate | 2024-01-18 |
PublicationDateYYYYMMDD | 2024-01-18 |
PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-18 day: 18 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC public health |
PublicationTitleAlternate | BMC Public Health |
PublicationYear | 2024 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | T Nyberg (17790_CR39) 2022; 399 17790_CR27 17790_CR26 17790_CR29 Y Goldberg (17790_CR33) 2021; 385 17790_CR28 S Chang (17790_CR43) 2021; 589 MW Tenforde (17790_CR34) 2021; 70 HN Altarawneh (17790_CR6) 2022; 387 17790_CR21 17790_CR20 N Bobrovitz (17790_CR37) 2023; 23 17790_CR23 MU Kraemer (17790_CR42) 2020; 368 JY Chun (17790_CR46) 2021 17790_CR22 S Carazo (17790_CR36) 2023; 23 F Blavin (17790_CR40) 2018; 37 HS Badr (17790_CR41) 2020; 20 FP Havers (17790_CR45) 2022; 182 JA Quesada (17790_CR31) 2021; 221 G Ogedegbe (17790_CR16) 2020; 3 T Hale (17790_CR47) 2021; 16 U Agrawal (17790_CR10) 2022; 400 17790_CR14 17790_CR13 17790_CR15 OT Ng (17790_CR9) 2022; 5 C Faes (17790_CR32) 2020; 17 MK Patel (17790_CR5) 2021; 39 S Khare (17790_CR30) 2021; 3 17790_CR19 EJ Haas (17790_CR7) 2021; 397 H Du (17790_CR24) 2023; 89 H Wienkes (17790_CR44) 2022; 5 OJ Watson (17790_CR11) 2022; 22 JH Kim (17790_CR4) 2021; 27 R Wang (17790_CR12) 2022; 10 E Dong (17790_CR18) 2020; 20 LR Baden (17790_CR1) 2021; 384 HN Altarawneh (17790_CR38) 2022; 386 T Hale (17790_CR25) 2020; 8 S Chenchula (17790_CR35) 2022; 94 J Sadoff (17790_CR2) 2021; 384 SJ Thomas (17790_CR3) 2021; 385 MA Gram (17790_CR8) 2022; 19 B Gallo Marin (17790_CR17) 2021; 31 |
References_xml | – volume: 22 start-page: 1293 year: 2022 ident: 17790_CR11 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00320-6 contributor: fullname: OJ Watson – ident: 17790_CR22 – volume: 27 start-page: 205 year: 2021 ident: 17790_CR4 publication-title: Nat Med doi: 10.1038/s41591-021-01230-y contributor: fullname: JH Kim – volume: 20 start-page: 1247 year: 2020 ident: 17790_CR41 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30553-3 contributor: fullname: HS Badr – ident: 17790_CR26 – ident: 17790_CR28 – volume: 386 start-page: 1288 year: 2022 ident: 17790_CR38 publication-title: N Engl J Med doi: 10.1056/NEJMc2200133 contributor: fullname: HN Altarawneh – volume: 10 start-page: 726 year: 2022 ident: 17790_CR12 publication-title: Vaccines doi: 10.3390/vaccines10050726 contributor: fullname: R Wang – year: 2021 ident: 17790_CR46 publication-title: SSRN Electron J doi: 10.2139/ssrn.3951778 contributor: fullname: JY Chun – volume: 385 start-page: 1761 year: 2021 ident: 17790_CR3 publication-title: N Engl J Med doi: 10.1056/NEJMoa2110345 contributor: fullname: SJ Thomas – volume: 3 start-page: 1049 year: 2021 ident: 17790_CR30 publication-title: China CDC Wkly doi: 10.46234/ccdcw2021.255 contributor: fullname: S Khare – volume: 3 start-page: e2026881 year: 2020 ident: 17790_CR16 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.26881 contributor: fullname: G Ogedegbe – ident: 17790_CR20 – volume: 89 start-page: 104482 year: 2023 ident: 17790_CR24 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2023.104482 contributor: fullname: H Du – volume: 23 start-page: 45 year: 2023 ident: 17790_CR36 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00578-3 contributor: fullname: S Carazo – volume: 399 start-page: 1303 year: 2022 ident: 17790_CR39 publication-title: The Lancet doi: 10.1016/S0140-6736(22)00462-7 contributor: fullname: T Nyberg – ident: 17790_CR13 – volume: 397 start-page: 1819 year: 2021 ident: 17790_CR7 publication-title: The Lancet doi: 10.1016/S0140-6736(21)00947-8 contributor: fullname: EJ Haas – volume: 384 start-page: 2187 year: 2021 ident: 17790_CR2 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 contributor: fullname: J Sadoff – ident: 17790_CR15 doi: 10.1016/j.vaccine.2023.05.056 – volume: 5 start-page: e220536 year: 2022 ident: 17790_CR44 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.0536 contributor: fullname: H Wienkes – volume: 384 start-page: 403 year: 2021 ident: 17790_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 contributor: fullname: LR Baden – volume: 5 start-page: e2228900 year: 2022 ident: 17790_CR9 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.28900 contributor: fullname: OT Ng – ident: 17790_CR14 doi: 10.1016/S0140-6736(23)00461-0 – ident: 17790_CR23 – volume: 94 start-page: 2969 year: 2022 ident: 17790_CR35 publication-title: J Med Virol doi: 10.1002/jmv.27697 contributor: fullname: S Chenchula – volume: 400 start-page: 1305 year: 2022 ident: 17790_CR10 publication-title: The Lancet doi: 10.1016/S0140-6736(22)01656-7 contributor: fullname: U Agrawal – volume: 20 start-page: 533 year: 2020 ident: 17790_CR18 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30120-1 contributor: fullname: E Dong – ident: 17790_CR27 – ident: 17790_CR19 – ident: 17790_CR29 – volume: 387 start-page: 21 year: 2022 ident: 17790_CR6 publication-title: N Engl J Med doi: 10.1056/NEJMoa2203965 contributor: fullname: HN Altarawneh – volume: 39 start-page: 4013 year: 2021 ident: 17790_CR5 publication-title: Vaccine doi: 10.1016/j.vaccine.2021.05.099 contributor: fullname: MK Patel – volume: 8 start-page: 30 year: 2020 ident: 17790_CR25 publication-title: Last Updat contributor: fullname: T Hale – volume: 17 start-page: 7560 year: 2020 ident: 17790_CR32 publication-title: Int J Environ Res Public Health doi: 10.3390/ijerph17207560 contributor: fullname: C Faes – ident: 17790_CR21 – volume: 31 start-page: 1 year: 2021 ident: 17790_CR17 publication-title: Rev Med Virol doi: 10.1002/rmv.2146 contributor: fullname: B Gallo Marin – volume: 368 start-page: 493 year: 2020 ident: 17790_CR42 publication-title: Science doi: 10.1126/science.abb4218 contributor: fullname: MU Kraemer – volume: 589 start-page: 82 year: 2021 ident: 17790_CR43 publication-title: Nature doi: 10.1038/s41586-020-2923-3 contributor: fullname: S Chang – volume: 16 start-page: e0253116 year: 2021 ident: 17790_CR47 publication-title: PLoS ONE doi: 10.1371/journal.pone.0253116 contributor: fullname: T Hale – volume: 19 start-page: e1003992 year: 2022 ident: 17790_CR8 publication-title: PLOS Med doi: 10.1371/journal.pmed.1003992 contributor: fullname: MA Gram – volume: 221 start-page: 109 year: 2021 ident: 17790_CR31 publication-title: Rev Clínica Esp Engl Ed doi: 10.1016/j.rceng.2020.08.002 contributor: fullname: JA Quesada – volume: 385 start-page: e85 year: 2021 ident: 17790_CR33 publication-title: N Engl J Med doi: 10.1056/NEJMoa2114228 contributor: fullname: Y Goldberg – volume: 182 start-page: 1071 year: 2022 ident: 17790_CR45 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2022.4299 contributor: fullname: FP Havers – volume: 23 start-page: 556 year: 2023 ident: 17790_CR37 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(22)00801-5 contributor: fullname: N Bobrovitz – volume: 70 start-page: 1156 year: 2021 ident: 17790_CR34 publication-title: Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7034e2 contributor: fullname: MW Tenforde – volume: 37 start-page: 299 year: 2018 ident: 17790_CR40 publication-title: Health Aff (Millwood) doi: 10.1377/hlthaff.2017.1166 contributor: fullname: F Blavin |
SSID | ssj0017852 |
Score | 2.4492009 |
Snippet | Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts.... Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating... Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease... In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on... BackgroundPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease... BACKGROUNDPopulation-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease... Abstract Background Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating... |
SourceID | doaj proquest gale crossref pubmed |
SourceType | Open Website Aggregation Database Index Database |
StartPage | 220 |
SubjectTerms | Analysis Care and treatment Clinical trials Cohort analysis Comorbidity Confounding (Statistics) COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines Critical components Diagnosis Disease control Disease transmission Expenditures Fatalities Government programs Health care Health policy Herd immunity Hospitalization Humans Infections Medical care, Cost of Mortality mRNA vaccines Outcome Assessment, Health Care Pandemics Population (statistical) Population-level Public health Public policy Regression analysis SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Social factors Statistical analysis Surveillance Time dependence United States United States - epidemiology Vaccination Vaccination rates Vaccine efficacy Vaccines Variables |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge0FCiDcLBRkJiQOymtixHXNBbWlVkCgIUdSb5UdSVULJspulV346M7E3sCBxjWeTrGc8-WY885mQF6p2WBkkGFLDsErWnhkfWhZNbEUlisK3mND_cKpOzqr35_I8J9xWuaxy4xNHRx37gDnyPW7G4EFJ-WbxneGpUbi7mo_QuE52OEQKfEZ2Do5OP32e9hF0LfmmVaZWeyvwxlgixCtWItEeu9r6HI2s_f_65r8Q5_jlOb5NbmXISPeTju-Qa013l9xM-Taa2ojukZ9_zDPNxVf0hwvhMqX7KFJCrKjrIj38-PXdW1Yamnogab8eYApg8LKjAAdpgqE0wdDX1NHFdMgX-4Y1RhS7kEaCZ3gtl1lN7pOz46Mvhycsn67AAoCygWlEaq2uQhli6UqjAwesBJeKCBBJNFEqr72MyouW-1i3BrBNUQnX1NJXbRAPyKzru-YRoSa0jUZBA8GiLpQHnOEFhlYA78CHzMmrzSTbRSLRsGPwUSubVGJBJXZUib2akwPUwySJBNjjhX55YfN6sk2hmti0lfaOVwEihFrJMpStk8ZJweGRL1GLFpfpsHTB5W4DeGEkvLL7gIxKAzMAkrtbkrC8wvbwxg5sXt4r-9sY5-T5NIy_xJK1runXKAPITAot9Zw8TPYz_SXcfAVHaR7__-ZPyA2OtlqUrKx3yWxYrpungIEG_ywb-i9VfARc priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA-1vggifnu1SgTBB4luNl8bQaRWSxXUF0_6FpJsIoWyV-_2Wn3zT3dms3d62kdfN7NsNjOT_CaZ-YWQx7rxmBkkGFLDMKmawGyImbW2zUKKqgoZN_Q_fNSHU_n-SB1tkdV1R-MALi4M7fA-qen85Nn3bz9egcO_HBy-0c8XMMdi4k8tGUf6PHZ-iVyukZgLU_nk71MF06h6VThz4Xsbi9PA4f_vTP0X_hzWoYPr5NoIIOle0fgNspW6m-Rq2X2jpajoFvn5x6jTMRWLnvkYj8vmH0WCiAX1XUv3P31594ZxS0tFJJ0tezBCaDzuKIBDWkApLaD0BfX0dH3lFzvBjCOKNUkD3TN0y48cJ7fJ9ODt5_1DNt61wCJAtJ4ZxG3ZyMhjyz23JtaAnOBR1QJgEqlVOpigWh1ErkPbZAtIp5LCp0YFmaO4Q7a7WZfuEWpjTgYFLYSOptIBUEcQGGgB2IMZZUKergbZnRZKDTeEIo12RSUOVOIGlbjzCXmNelhLIh328GA2_-pG73Kp0qlNWZrgaxkhXmi04pFnr6xXooZPPkEtOjSjfu6jH2sPoMNIf-X2ACdxCyMAkrsbkuBscbN5ZQduZauutkNcq5WakEfrZnwTE9i6NFuiDOA0JYwyE3K32M_6l_AoFqZNu_M_fvU-uVKjRVec8WaXbPfzZXoAuKkPDwdn-AUBKxOQ priority: 102 providerName: Scholars Portal |
Title | Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38238709 https://www.proquest.com/docview/2925601655 https://search.proquest.com/docview/2917553757 https://doaj.org/article/e06edef47ba24c7298651c1fa59a5323 |
Volume | 24 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NaxQxFA9aL4KI3x1blwiCBwmdTCZf3rpr1yq0SrGyeAlJJgMFmS3dXXvtn-57k9mlqwcvXjKQvIFM3kvye5n3fiHkjTIeI4MEQ2oYVksTmA2xZY1tWlGLsgwtHuifnKrj8_rzTM5uXfWFMWGZHjgP3EEqVWpSW-vgqzoCFDRK8shbL62Xoso8n6VdO1PD_wNtZLVOkTHqYAGrMIYGVTXjSLDHrre2oZ6t_-81-Q-k2e8400fk4QAV6WHu4mNyJ3VPyIN8zkZz-tBTcnNrfOkQdEV_-Rgv8jEfRSqIBfVdQydfvn_6wLilOfeRzldLMDdovOgowECa4SfN8PM99fRyc7kX-4mxRRSzj3piZ-iWH9hMnpHz6dG3yTEbblVgEcDYkmlEaK2uI48N99zqWAFGgqqyAWgkUiNV0EE2Koi2Co1pLWCashY-GRnqNornZKebd2mXUBvbpFHQgpOoSxUAXwSBLhXAOlg7CvJuPcjuMpNnuN7pMMpllThQietV4q4LMkY9bCSR-LqvAHNwgzm4f5lDQd6iFh1Oz-WVj37IMoAOI9GVOwRExC2MAEjub0nCtIrbzWs7cMO0XrjK9h6skrIgrzfN-CaGqnVpvkIZQGRSaKkL8iLbz-aT8KcrLJD25f_41D1yv0KLLjnjZp_sLK9W6RUgpGUYkbt6pqE0E47l9OOI3BsfnX49g2dvbKN-ukB5Uhsoz8Y_fgNXHBNT |
link.rule.ids | 315,783,787,867,2109,12070,12237,12779,21402,24332,27938,27939,31733,31734,33280,33281,33387,33388,33758,33759,38530,43324,43593,43614,43819,43909 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagPYCEeD8WChgJiQNym4cdx1xQKVRbaMulRb1ZthOjqlWy7GapxImfzkzsBLZIHLjGk8TJjMefxzOfCXlZlAYzg3KG1DCMi9IyZZ1nlap8zvMksR4D-geHxfSYfzwRJzHgtohplYNP7B111TqMkW9lql88FEK8nX1jeGoU7q7GIzSuknWYWBOw6vWdz1_23o_7CLIU2VAqUxZbC_DGmCKUcZYi0R67WJmOetb-v33zJcTZzzy7t4ge-hwSTs42l53ddD8u0Tn-_0fdJjcjKKXbwYrukCt1c5fcCBE9GgqV7pGff2iSxvQu-t04dxoCihRJJxbUNBXt_w5LFQ1VlrRddtAfaDxtKABOGoAuDUD3DTV0Nh4jxs4xi4linVNPIQ3dMpE35T453v1wtDNl8fwG5gD2dUwiFvSSu9RVqUmVdBmgMbiUVADC8roShZVWVIXNfWar0itATwnPTV0Ky73LH5C1pm3qR4Qq52uJgqBkLpPCApKxOS7eAECCl5qQ14Ma9SzQdOh-eVMWOihdg9J1r3R9MSHvUNOjJFJs9xfa-VcdR6yuk6Kuas-lNRl3sAYpC5G61BuhjMgzeOUrtBONjqCbG2diPQN0GCm19DZgr1TBHwDJjRVJGMButXkwDh0dyEL_towJeTE2452YFNfU7RJlAPuJXAo5IQ-DhY6fhNu74IrV438__Dm5Nj062Nf7e4efnpDrGY6MJGVpuUHWuvmyfgqIq7PP4rD6BSfXKjc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+between+vaccination+rates+and+COVID-19+health+outcomes+in+the+United+States%3A+a+population-level+statistical+analysis&rft.jtitle=BMC+public+health&rft.au=Hongru+Du&rft.au=Samee+Saiyed&rft.au=Lauren+M.+Gardner&rft.date=2024-01-18&rft.pub=BMC&rft.eissn=1471-2458&rft.volume=24&rft.issue=1&rft.spage=1&rft.epage=14&rft_id=info:doi/10.1186%2Fs12889-024-17790-w&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e06edef47ba24c7298651c1fa59a5323 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2458&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2458&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2458&client=summon |